In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465

British Journal of Haematology

Volumn 147, Issue 5, 2009, Pages 672-676

  Negri, Joseph M ^a   McMillin, Douglas W ^a   Delmore, Jake ^a   Mitsiades, Nicholas ^a   Hayden, Patrick ^a   Klippel, Steffen ^a   Hideshima, Teru ^a   Chauhan, Dharminder ^a   Munshi, Nikhil C ^a   Buser, Carolyn A ^b   Pollard, John ^c   Richardson, Paul G ^a   Anderson, Kenneth C ^a   Mitsiades, Constantine S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Vertex Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Kinase inhibition; Microenvironment; Myeloma

Indexed keywords

AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; UNCLASSIFIED DRUG; VE 465;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROENVIRONMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; STROMA CELL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL COMMUNICATION; CELL CYCLE; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HEMATOPOIETIC STEM CELLS; HUMANS; MULTIPLE MYELOMA; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 70449387257     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07891.x     Document Type: Article

References (14)

1. Bischoff, J.R., Anderson, L., Zhu, Y., Mossie, K., Ng, L., Souza, B., Schryver, B., Flanagan, P., Clairvoyant, F., Ginther, C., Chan, C.S., Novotny, M., Slamon, D.J. Plowman, G.D. (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO Journal, 17, 3052 3065.
2. Carvajal, R.D., Tse, A. Schwartz, G.K. (2006) Aurora kinases: new targets for cancer therapy. Clinical Cancer Research, 12, 6869 6875.
3. Chng, W.J., Braggio, E., Mulligan, G., Bryant, B., Remstein, E., Valdez, R., Dogan, A. Fonseca, R. (2008) The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood, 111, 1603 1609.
4. Evans, R., Naber, C., Steffler, T., Checkland, T., Keats, J., Maxwell, C., Perry, T., Chau, H., Belch, A., Pilarski, L. Reiman, T. (2008) Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leukaemia & Lymphoma, 49, 559 569.
5. Gritsko, T.M., Coppola, D., Paciga, J.E., Yang, L., Sun, M., Shelley, S.A., Fiorica, J.V., Nicosia, S.V. Cheng, J.Q. (2003) Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clinical Cancer Research, 9, 1420 1426.
6. Li, D., Zhu, J., Firozi, P.F., Abbruzzese, J.L., Evans, D.B., Cleary, K., Friess, H. Sen, S. (2003) Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clinical Cancer Research, 9, 991 997.
7. Mitsiades, C.S., Treon, S.P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T. Anderson, K.C. (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood, 98, 795 804.
8. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A. Anderson, K.C. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 101, 540 545.
9. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487 2498. (Pubitemid 41007864)
10. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, R.L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E. Anderson, K.C. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, 3458 3464.
11. Rubin, E.H., Shapiro, G.I., Stein, M.N., Watson, P., Bergstrom, D., Xiao, A., Clark, J.B., Freedman, S.J. Eder, J.P. (2006) A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. Journal of Clinical Oncology, 24, 123S.
12. Shi, Y., Reiman, T., Li, W., Maxwell, C.A., Sen, S., Pilarski, L., Daniels, T.R., Penichet, M.L., Feldman, R. Lichtenstein, A. (2007) Targeting aurora kinases as therapy in multiple myeloma. Blood, 109, 3915 3921.
13. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565 1571.
14. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133 2142. (Pubitemid 350146108)